Buscar
Pharvaris NV
PHVSAñadir a la lista de seguimiento
29.830USD
-0.870-2.84%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.95BCap. mercado
PérdidaP/E TTM
Más Datos de Pharvaris NV Compañía
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Información de Pharvaris NV
Símbolo de cotizaciónPHVS
Nombre de la empresaPharvaris NV
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoModig (Berndt B.A.E)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
DirecciónEmmy Noetherweg 2
CiudadLEIDEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal2333 BK
Teléfono31712036410
Sitio Webhttps://pharvaris.com/
Símbolo de cotizaciónPHVS
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoModig (Berndt B.A.E)
Ejecutivos de Pharvaris NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-1.57%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.84K
--
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
201.62K
+99.60%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
+54.39%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
106.11K
+48.26%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.28K
-5.73%
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-1.57%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.84K
--
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
201.62K
+99.60%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
+54.39%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
106.11K
+48.26%
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: jue., 19 de feb
Actualizado: jue., 19 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
General Atlantic LLC
11.53%
Fidelity Management & Research Company LLC
9.19%
Foresite Capital Management, LLC
6.86%
VenBio Partners LLC
6.66%
Viking Global Investors LP
5.24%
Otro
60.52%
Accionistas
Accionistas
Proporción
General Atlantic LLC
11.53%
Fidelity Management & Research Company LLC
9.19%
Foresite Capital Management, LLC
6.86%
VenBio Partners LLC
6.66%
Viking Global Investors LP
5.24%
Otro
60.52%
Tipos de accionistas
Accionistas
Proporción
Private Equity
31.30%
Hedge Fund
20.13%
Investment Advisor
18.48%
Investment Advisor/Hedge Fund
10.17%
Venture Capital
4.94%
Individual Investor
4.89%
Research Firm
0.63%
Pension Fund
0.07%
Bank and Trust
0.07%
Otro
9.33%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
165
59.26M
90.60%
-451.33K
2025Q4
152
61.74M
96.38%
+11.01M
2025Q3
118
49.64M
77.50%
-950.63K
2025Q2
125
52.21M
81.51%
-1.38M
2025Q1
125
53.89M
99.06%
+200.61K
2024Q4
123
53.45M
98.98%
+218.03K
2024Q3
114
53.86M
99.73%
+1.03M
2024Q2
83
52.08M
96.43%
-141.66K
2024Q1
76
49.63M
98.30%
-831.88K
2023Q4
69
47.76M
94.74%
+8.60M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
General Atlantic LLC
8.03M
12.54%
--
--
Dec 31, 2025
Fidelity Management & Research Company LLC
6.40M
9.99%
--
--
Dec 31, 2025
Foresite Capital Management, LLC
4.78M
7.46%
--
--
Dec 31, 2025
VenBio Partners LLC
4.64M
7.24%
--
--
Dec 31, 2025
Viking Global Investors LP
3.65M
5.7%
--
--
Dec 31, 2025
EQT Partners AB
3.42M
5.35%
--
--
Dec 31, 2025
Deerfield Management Company, L.P.
3.13M
4.88%
+683.58K
+27.99%
Dec 31, 2025
Bain Capital Life Sciences Investors, LLC
2.80M
4.37%
-379.19K
-11.92%
Dec 31, 2025
Wellington Management Company, LLP
1.91M
2.98%
+171.05K
+9.86%
Dec 31, 2025
Commodore Capital LP
1.89M
2.95%
-529.03K
-21.87%
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
ALPS Medical Breakthroughs ETF
0.59%
iShares MSCI Netherlands ETF
0.23%
SPDR S&P International Small Cap ETF
0.08%
iShares MSCI Europe Small-Cap ETF
0.04%
iShares MSCI EAFE Small-Cap ETF
0.02%
Fidelity Nasdaq Composite Index ETF
0.01%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0.01%
Avantis International Small Cap Equity ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
Ver más
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.87%
ALPS Medical Breakthroughs ETF
Proporción0.59%
iShares MSCI Netherlands ETF
Proporción0.23%
SPDR S&P International Small Cap ETF
Proporción0.08%
iShares MSCI Europe Small-Cap ETF
Proporción0.04%
iShares MSCI EAFE Small-Cap ETF
Proporción0.02%
Fidelity Nasdaq Composite Index ETF
Proporción0.01%
Xtrackers MSCI Eurozone Hedged Eqty ETF
Proporción0.01%
Avantis International Small Cap Equity ETF
Proporción0%
First Trust IPOX Europe Equity Opportunities ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
